Versant Venture Management, LLC

Q2 2025 13F Holdings

  • Location
    san francisco, CA
  • Num holdings

    8

  • Value ($000)

    $82,137

  • Date Filed
    08/11/2025
  • Form type
    13F-HR
  • CIK
    0001560009
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
GLUE
GLUE

Monte Rosa Therapeutics, Inc.

COMMON STOCK
61225M102
$25.49M
31 %

5,652,922

---

CRISPR Therapeutics AG

COMMON SHARES
H17182108
$24.25M
30 %

498,558

---

Jade Biosciences, Inc.

COMMON STOCK
008064206
$15.24M
19 %

1,525,820

SKYE
SKYE

Skye Bioscience, Inc.

COMMON STOCK
83086J200
$8.39M
10 %

2,007,704

RPTX
RPTX

Repare Therapeutics, Inc.

COMMON STOCK
760273102
$3.68M
5 %

2,646,657

CTNM
CTNM

Contineum Therapeutics, Inc.

COMMON STOCK
21217B100
$2.15M
3 %

542,628

TPST
TPST

Tempest Therapeutics, Inc.

COMMON STOCK
87978U108
$1.83M
2 %

269,772

ADVM
ADVM

Adverum Biotechnologies, Inc.

COMMON STOCK
00773U108
$1.09M
1 %

506,821

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 8 of 8